IL17A and metabolic dysfunction-associated steatohepatitis: Taken together, Inhibition of hepatocyte-IL-17A production could be an important mechanism for FGF21 to prevent NASH via a negative feedback loop on TLR4/NF-κB/IL-17A signaling.